11 May 2023 in Nature Reviews Bioengineering
Body-based biomolecular sensing systems, including wearable, implantable and consumable sensors allow comprehensive health-related monitoring. Glucose sensors have long dominated wearable bioanalysis applications owing to their robust continuous detection of glucose, which has not yet been achieved for other biomarkers. However, access to diverse biological fluids and the development of reagentless sensing approaches may enable the design of body-based sensing systems for various analytes. Importantly, enhancing the selectivity and sensitivity of biomolecular sensors is essential for biomarker detection in complex physiological conditions. In this Review, we discuss approaches for the signal amplification of biomolecular sensors, including techniques to overcome Debye and mass transport limitations, and selectivity improvement, such as the integration of artificial affinity recognition elements. We highlight reagentless sensing approaches that can enable sequential real-time measurements, for example, the implementation of thin-film transistors in wearable devices. In addition to sensor construction, careful consideration of physical, psychological and security concerns related to body-based sensor integration is required to ensure that the transition from the laboratory to the human body is as seamless as possible.
5 June 2023 in Nature Chemistry
15 October 2025 in Nature Nanotechnology
11 September 2023 in Nature Communications
Exosomal PD-L1 (exoPD-L1) has recently received significant attention as a biomarker predicting immunotherapeutic responses involving the PD1/PD-L1 pathway. However, current technologies for exosomal analysis rely primarily on bulk measurements that do not consider the heterogeneity found within exosomal subpopulations. Here, we present a nanoscale cytometry platform NanoEPIC, enabling phenotypic sorting and exoPD-L1 profiling from blood plasma. We highlight the efficacy of NanoEPIC in monitoring anti-PD-1 immunotherapy through the interrogation of exoPD-L1. NanoEPIC generates signature exoPD-L1 patterns in responders and non-responders. In mice treated with PD1-targeted immunotherapy, exoPD-L1 is correlated with tumor growth, PD-L1 burden in tumors, and the immune suppression of CD8+ tumor-infiltrating lymphocytes. Small extracellular vesicles (sEVs) with different PD-L1 expression levels display distinctive inhibitory effects on CD8 + T cells. NanoEPIC offers robust, high-throughput profiling of exosomal markers, enabling sEV subpopulation analysis. This platform holds the potential for enhanced cancer screening, personalized treatment, and therapeutic response monitoring.
7 August 2025 in Nature Biomedical Engineering
16 October 2026 in ChemRxiv
Nucleic acid aptamers provide a simple, cost-effective alternative to antibodies for targeting biomolecular analytes from ions to large protein complexes. However, the interactions of these nucleic-acid based structures in vivo remains largely uncharacterized. Here, we report the seemingly pervasive electrostatic association between nucleic acids and high isoelectric point proteins under biological conditions. Such non-specific binding runs the risk of convoluting aptamer selection and validation, while also potentially interfering with nucleic acid-based nanotechnologies in vivo. Through our explorations, we identify several methods to disentangle sequence-specific aptamer interactions from non-specific electrostatic association, allowing for discrimination between binding modes. We also identify dissociation rate (koff) and equilibrium binding response (Req) as potentially better discriminators than KD for isolating and validating true sequence-specific aptamers.